A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2017
At a glance
- Drugs BPX 201 (Primary) ; Rimiducid
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Bellicum Pharmaceuticals
- 11 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Sep 2017.
- 10 Jun 2017 Biomarkers information updated
- 25 Mar 2016 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.